ultragenyx pharmaceutical - RARE
RARE
Close Chg Chg %
14.88 -0.57 -3.83%
Pre-Market
14.31
-0.57 (3.83%)
Volume: 4.58M
Last Updated:
Sep 9, 2026, 4:00 PM EDT
Company Overview: ultragenyx pharmaceutical - RARE
RARE Key Data
| Open $14.76 | Day Range 14.27 - 15.19 |
| 52 Week Range 13.81 - 39.89 | Market Cap $1.51B |
| Shares Outstanding 98.59M | Public Float 89.92M |
| Beta 0.32 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$5.84 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 4.11M |
RARE Performance
| 1 Week | -2.75% | ||
| 1 Month | -42.57% | ||
| 3 Months | -38.89% | ||
| 1 Year | -50.91% | ||
| 5 Years | -85.37% |
RARE Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
20
Full Ratings ➔
About ultragenyx pharmaceutical - RARE
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.
RARE At a Glance
Ultragenyx Pharmaceutical, Inc.
60 Leveroni Court
Novato, California 94949
| Phone | 1-415-483-8800 | Revenue | 673.00M | |
| Industry | Pharmaceuticals: Major | Net Income | -575,000,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 20.129% | |
| Fiscal Year-end | 12 / 2026 | Employees | 1,371 | |
| View SEC Filings |
RARE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.37 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.668 |
| Enterprise Value to Sales | 4.211 |
| Total Debt to Enterprise Value | 0.442 |
RARE Efficiency
| Revenue/Employee | 490,882.567 |
| Income Per Employee | -419,401.896 |
| Receivables Turnover | 4.233 |
| Total Asset Turnover | 0.443 |
RARE Liquidity
| Current Ratio | 2.477 |
| Quick Ratio | 2.341 |
| Cash Ratio | 1.805 |
RARE Profitability
| Gross Margin | 79.792 |
| Operating Margin | -79.495 |
| Pretax Margin | -84.844 |
| Net Margin | -85.438 |
| Return on Assets | -37.886 |
| Return on Equity | -656.029 |
| Return on Total Capital | -49.061 |
| Return on Invested Capital | -52.364 |
RARE Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 106.826 |
| Total Debt to Total Assets | 81.723 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 99.915 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Ultragenyx Pharmaceutical - RARE
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 363.33M | 434.25M | 560.23M | 673.00M | |
Sales Growth
| +3.39% | +19.52% | +29.01% | +20.13% | |
Cost of Goods Sold (COGS) incl D&A
| 43.32M | 67.42M | 106.77M | 136.00M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 18.20M | 26.01M | 35.54M | 35.00M | |
Depreciation
| 15.00M | 22.21M | 30.04M | 27.00M | |
Amortization of Intangibles
| 3.20M | 3.80M | 5.50M | 8.00M | |
COGS Growth
| +48.12% | +55.62% | +58.38% | +27.38% | |
Gross Income
| 320.01M | 366.83M | 453.46M | 537.00M | |
Gross Income Growth
| -0.67% | +14.63% | +23.61% | +18.42% | |
Gross Profit Margin
| +88.08% | +84.48% | +80.94% | +79.79% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 968.93M | 936.04M | 989.43M | 1.07B | |
Research & Development
| 690.79M | 626.24M | 667.82M | 723.00M | |
Other SG&A
| 278.14M | 309.80M | 321.61M | 349.00M | |
SGA Growth
| +37.65% | -3.39% | +5.70% | +8.34% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 19.30M | (397.00K) | 1.11M | |
EBIT after Unusual Expense
| (668.22M) | (568.81M) | (537.09M) | (535.00M) | |
Non Operating Income/Expense
| 9.51M | 26.35M | 32.54M | 26.00M | |
Non-Operating Interest Income
| 11.07M | 26.69M | 36.51M | 25.00M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 43.02M | 66.00M | 63.04M | 62.00M | |
Interest Expense Growth
| +46.20% | +53.44% | -4.49% | -1.65% | |
Gross Interest Expense
| 43.02M | 66.00M | 63.04M | 62.00M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (701.73M) | (608.46M) | (567.59M) | (571.00M) | |
Pretax Income Growth
| -54.91% | +13.29% | +6.72% | -0.60% | |
Pretax Margin
| -193.14% | -140.12% | -101.31% | -84.84% | |
Income Tax
| 5.70M | (1.82M) | 1.60M | 4.00M | |
Income Tax - Current - Domestic
| - | 6.06M | (3.19M) | 224.00K | |
Income Tax - Current - Foreign
| 1.27M | 3.13M | 2.75M | 4.00M | |
Income Tax - Deferred - Domestic
| - | - | (1.64M) | (1.61M) | - |
Income Tax - Deferred - Foreign
| - | - | (157.00K) | (1.37M) | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (707.42M) | (606.64M) | (569.18M) | (575.00M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (707.42M) | (606.64M) | (569.18M) | (575.00M) | |
Net Income Growth
| -55.81% | +14.25% | +6.17% | -1.02% | |
Net Margin Growth
| -194.71% | -139.70% | -101.60% | -85.44% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (707.42M) | (606.64M) | (569.18M) | (575.00M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (707.42M) | (606.64M) | (569.18M) | (575.00M) | |
EPS (Basic)
| -10.1184 | -8.2487 | -6.2867 | -5.8316 | |
EPS (Basic) Growth
| -51.09% | +18.48% | +23.79% | +7.24% | |
Basic Shares Outstanding
| 69.91M | 73.54M | 90.54M | 98.60M | |
EPS (Diluted)
| -10.1184 | -8.2487 | -6.2867 | -5.8316 | |
EPS (Diluted) Growth
| -51.09% | +18.48% | +23.79% | +7.24% | |
Diluted Shares Outstanding
| 69.91M | 73.54M | 90.54M | 98.60M | |
EBITDA
| (630.72M) | (543.20M) | (500.43M) | (500.00M) | |
EBITDA Growth
| -71.16% | +13.88% | +7.87% | +0.09% | |
EBITDA Margin
| -173.59% | -125.09% | -89.33% | -74.29% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 30.158 | |
| Number of Ratings | 20 | Current Quarters Estimate | -0.869 | |
| FY Report Date | 09 / 2026 | Current Year's Estimate | -3.997 | |
| Last Quarter’s Earnings | -0.90 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -5.83 | Next Fiscal Year Estimate | -0.70 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 20 | 20 | 19 | 20 |
| Mean Estimate | -0.87 | -0.33 | -4.00 | -0.70 |
| High Estimates | 0.75 | 1.50 | -1.18 | 4.50 |
| Low Estimate | -1.29 | -1.20 | -5.23 | -2.56 |
| Coefficient of Variance | -69.24 | -243.35 | -29.92 | -226.17 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 9 | 16 | 15 |
| OVERWEIGHT | 1 | 2 | 2 |
| HOLD | 10 | 2 | 2 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Buy | Buy |
SEC Filings for Ultragenyx Pharmaceutical - RARE
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Ultragenyx Pharmaceutical - RARE
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Sep 9, 2026 | Theodore A. Huizenga SVP, Chief Accounting Officer | 69,146 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $13.99 per share | 967,352.54 |
| May 7, 2026 | Eric Crombez EVP and Chief Medical Officer | 111,189 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.96 per share | 2,775,277.44 |
| Apr 21, 2026 | Emil D. Kakkis President & CEO; Director | 735,739 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 21, 2026 | Emil D. Kakkis President & CEO; Director | 132,693 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 21, 2026 | John Richard Pinion See Remarks | 133,142 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 21, 2026 | John Richard Pinion See Remarks | 79,936 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 21, 2026 | Erik C. Harris EVP & Chief Commercial Officer | 118,410 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 21, 2026 | Erik C. Harris EVP & Chief Commercial Officer | 49,960 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 21, 2026 | Howard Horn Chief Financial Officer | 115,025 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 21, 2026 | Howard Horn Chief Financial Officer | 59,952 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 21, 2026 | Dennis Karl Huang See Remarks | 147,845 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 21, 2026 | Dennis Karl Huang See Remarks | 79,936 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 21, 2026 | Eric Crombez EVP and Chief Medical Officer | 59,952 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 21, 2026 | Karah Parschauer EVP and Chief Legal Officer | 95,715 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 21, 2026 | Karah Parschauer EVP and Chief Legal Officer | 49,960 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |